Although one study using 10-days of decitabine reported a marrow remission rate of 100% in TP53-mutated patients with AML or MDS [61], the results have not been confirmed in subsequent studies, including a randomized study of 5-day versus 10-day schedules of decitabine as first line therapy for older patients with AML [62]. This evidence concerns the gene TP53 and acute myeloid leukemia.